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The clinical outcome is poor for patients who have local recurrence after radical cystectomy for bladder
cancer. We investigated clinical outcomes of patients with isolated local recurrence and with both local
recurrence and distant metastasis. From 1990 to 2006, 299 patients who had bladder cancer without distant
metastasis underwent radical cystectomy in our hospital. We included 200 patients who had a negative
surgical margin at radical cystectomy and urothelial carcinoma, and who had not had upper urinary tract
cancer or other active cancer. Fifteen (7.5％) had isolated local recurrence (isolated group) and 18 (9.0％)
had local recurrence and distant metastasis simultaneously (simultaneous group). The median overall
survival time and that for survival after recurrence were 24 and 13 months, respectively, in the isolated group,
and 18 and 5 months, respectively, in the simultaneous group. Although we did not ﬁnd a signiﬁcant
difference in overall survival (p＝0.314), there was one for survival after recurrence (p＝0.001) between the
two groups. In the isolated group, 13 died of cancer, 1 of another cause and 1 was alive without cancer.
All patients in the simultaneous group died of cancer. Three patients in the isolated group underwent
surgery for residual tumors after systemic chemotherapy, and 2 of the 3 survived for more than 2 years after
recurrence. Some patients with isolated local recurrence beneﬁted from multimodal therapies. In these
patients, surgery for the residual tumor after systemic chemotherapy was likely to be effective if a negative
margin was achieved in surgical specimens.
(Hinyokika Kiyo 55 : 469-473, 2009)





















対 象 と 方 法
1990年から2006年までに札幌医科大学泌尿器科で
は，遠隔転移を有さない (cT1-4N0-2M0 : 1997年改訂






























生存率は Kaplan-Meier 法にて算出し，Log-rank test
を用い検定した．群間比較は Mann-Whitney U-test お













レジメンは，MVAC 療法 (M : methotrexate，V : vin-
blastine，A : doxorubicin，C : cisplatin) 16例，GC 療法
(G : gemcitabine，C : cisplatin) 1 例，TIN 療法 (T :
paclitaxel，I : ifosfamide，N : nedaplatin) 2例であった．
また，MVAC 療法が無効であった 1例にGC 療法を，
GC 療法が無効であった 1例にMVAC 療法を行った．






≦T1 14 1 ( 7)
T2 72 11 ( 15)
T3 55 10 ( 18)
T4 46 10 ( 22)
N＋ 13 1 ( 8)
病理病期分類*1
T0 27 1 ( 4)
Tis/a/1 38 4 ( 11)
T2 36 8 ( 22)
T3 35 5 ( 14)
T4 23 3 ( 13)
N＋ 41 12 ( 29)
病理組織分類
TURBT 切除標本
UC 175 26 ( 15)
UC＞SCC 16 6 ( 38)
UC＞AC 9 1 ( 11)
全摘標本
UC 149 24 ( 16)
UC＞SCC 20 7 ( 35)
UC＞AC 3 0 ( 0)
UC＞SCC＞AC 1 1 (100)
No malignancy 27 1 ( 4)
*1 TNM classiﬁcation 5th edition (1997). UC : urothelial
carcinoma, SCC : squamous cell carcinoma, AC : adeno-
carcinoma.
Table 2. Characteristics and outcomes of patients












性 別 男 9 15 NS
女 6 3




No malignancy 1 0
臨床病期分類 ≦cT2 6 6 NS
≧cT3 9 12
病理病期分類 ≦pT2 7 6 NS
≧pT3 8 12
所属リンパ節
転移 pN− 11 10 NS
pN＋ 4 8







転 帰 生 存 1 0 NS
癌 死 13 18
他因死 1 0
UC : urothelial carcinoma, SCC : squamous cell carcinoma, AC :
adenocarcinoma, NS : No signiﬁcance.







性）， 1 例で PR（部分奏効＝切除断端陽性）が得ら

























1 55 同時 cT2N0 MVAC pT2N0 無 22 4 MVAC PD 癌死
2 55 同時 cT3N0 無 pT1N0 無 16 5 MVAC PD 癌死
3 51 同時 cT2N0 無 pT2N1 無 6 5 MVAC/XRT PD 癌死
4 48 同時 cT2N0 MVAC pT2N0 無 18 6 MVAC/XRT PD 癌死
5 72 同時 cT2N0 無 pT1N0 無 13 7 MVAC PD 癌死
6 59 同時 cT4N0 MVAC pT4N2 MVAC 71 7 MVAC NC 癌死
7 57 同時 cT2N0 無 pT3N2 無 17 8 MVAC PD 癌死
8 58 同時 cT4N0 無 pT4N2 MVAC 12 9 TIN PR 癌死
9 56 同時 cT4N0 無 pT3N0 無 5 10 MVAC/XRT PD 癌死
10 52 同時 cT4N0 無 pT3N2 MVAC 6 12 TIN PD 癌死
11 49 同時 cT3N0 MVAC pT2N0 無 20 13 MVAC/XRT PD 癌死
12 77 単独 cT3N0 無 pT2N0 無 11 5 XRT NC 癌死
13 65 単独 cT2N0 無 pT3N0 無 8 6 MVAC NC 癌死
14 53 単独 cT4N0 無 pT3N0 MVAC 18 10 XRT NC 癌死
15 65 単独 cT4N1 無 pT4N1 MVAC 7 13 XRT PD 癌死
16 75 単独 cT2N0 MVAC pT0N0 無 11 14 MVAC/XRT PD 癌死
17 49 単独 cT2N0 MVAC pT2N0 無 31 14 MVAC PD 癌死
18 62 単独 cT2N0 無 pT2N0 無 54 14 MVAC/Op NC→PR 癌死
19 74 単独 cT3N0 無 pT3N2 無 8 17 MVAC PD 癌死
20 78 単独 cT4N0 無 pT4N0 無 6 22 GC/MVAC NC 癌死
21 68 単独 cT2N0 無 pT2N0 無 6 30 MVAC/GC/Op NC→CR 癌死
22 56 単独 cT1N0 無 pTisN0 無 102 45 MVAC/Op NC→CR 生存
同時 :局所遠隔転移同時再発，単独 : 局所単独再発，MVAC :MVAC 療法，GC : GC 療法，TIN : TIN 療法，XRT :放射線
療法，Op :手術，CR : 完全奏効，PR : 部分奏効，NC : 変化 なし，PD :増悪．
泌55,08,01-1
Fig. 1. Overall survival after radical cystectomy.
泌55,08,01-2















摘除にて CR が得られたが，その 9カ月後に再再発
（肺転移，肝転移，局所再発）を来たした．救済化学





しかしその後，強度変調放射線治療 (70 Gy) と Cs-
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